PFE.BA - Pfizer Inc.

Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
804.00
0.00 (0.00%)
At close: 1:02PM ART
Stock chart is not supported by your current browser
Previous Close804.00
Open804.00
Bid808.00 x 0
Ask0.00 x 0
Day's Range804.00 - 804.00
52 Week Range336.60 - 900.00
Volume2,736
Avg. Volume154
Market Cap9.297T
Beta (3Y Monthly)0.85
PE Ratio (TTM)203.08
EPS (TTM)3.96
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2015-02-04
1y Target EstN/A
  • Bulls bet on this biopharma company. Plus, the update on ...
    CNBC Videos2 days ago

    Bulls bet on this biopharma company. Plus, the update on ...

    "Halftime Report" traders Jon and Pete Najarian spot unusual options activity in shares of Macy's and Pfizer.

  • Fiserv to buy First Data in $22B all-stock deal
    CNBC Videos4 days ago

    Fiserv to buy First Data in $22B all-stock deal

    Fiserv announced plans to buy First Data in an all-stock transaction the companies valued at $22 billion.

  • Would Pfizer Shareholders Win With an Acquisition of Amarin?
    Motley Fool3 hours ago

    Would Pfizer Shareholders Win With an Acquisition of Amarin?

    A Pfizer buyout of Amarin is still just a rumor. But rumors sometimes turn into reality.

  • Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?
    Motley Fool3 hours ago

    Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?

    The answer: It's complicated.

  • GuruFocus.com3 days ago

    The Stable Value Stock Is Built to Weather Market Storms

    It is hard to say anything about McKesson (MCK) that we have not said before -- it is a high-quality business with extremely cheap shares. McKesson stock is not just cheap -- it's incredibly cheap. McKesson, for example, benefited tremendously when billions of dollars worth of branded drugs lost their patents and went generic between 2009 and 2015.

  • Associated Press4 days ago

    Court rules against Pfizer in religious discrimination suit

    TRENTON, N.J. (AP) — A woman who said she was fired by a major pharmaceutical company because of her religious beliefs won a court victory Wednesday when a state appeals panel ruled that she didn't agree in an online form to waive her rights to sue.

  • Why Ligand Pharmaceuticals Tanked 25%
    Market Realist4 days ago

    Why Ligand Pharmaceuticals Tanked 25%

    Why Ligand Pharmaceuticals Tanked 25%Ligand PharmaceuticalsToday, US pharmaceutical firm Ligand Pharmaceuticals (LGND) fell 25% from yesterday’s closing price to a low of $98.86 for the day. At the same time, other pharmaceutical companies Amarin

  • Is Pfizer a Buy?
    Motley Fool4 days ago

    Is Pfizer a Buy?

    America's largest pharmaceutical company is about to show investors something they haven't seen in a while.

  • Markit4 days ago

    See what the IHS Markit Score report has to say about Pfizer Inc.

    # Pfizer Inc ### NYSE:PFE View full report here! ## Summary * Perception of the company's creditworthiness is neutral * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for PFE with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $13.64 billion over the last one-month into ETFs that hold PFE are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Neutral The current level displays a neutral indicator. PFE credit default swap spreads are within the middle of their range for the last three years. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Why Amarin Is Soaring in First Half of January
    Market Realist5 days ago

    Why Amarin Is Soaring in First Half of January

    Why Amarin Is Soaring in First Half of JanuaryStock price hikeOn January 11, Amarin (AMRN) closed at $18.00, which is 1.91% lower than its previous closing price. However, on January 10, 2019, the company closed at $18.35, almost 22% higher than its

  • Here's How Pfizer Gained 20.5% in 2018
    Motley Fool6 days ago

    Here's How Pfizer Gained 20.5% in 2018

    While its industry was getting crushed, this big pharma surged forward.

  • Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe
    Investor's Business Daily6 days ago

    Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe

    House Democrats launched an investigation into a dozen pharmaceutical companies on Monday, focusing on drug prices and prompting shares to topple. AstraZeneca and Novo Nordisk fell hard.

  • This Biotech Stock Plunged On Its Looming Rivalry With Pfizer
    Investor's Business Daily6 days ago

    This Biotech Stock Plunged On Its Looming Rivalry With Pfizer

    Alnylam dipped Monday after the FDA agreed to review an amyloidosis treatment from Pfizer in just six months. Pfizer's drug would treat patients with abnormal protein building in the heart.

  • House Dems announce sweeping investigation of drug pricing
    Associated Press6 days ago

    House Dems announce sweeping investigation of drug pricing

    House Democrats announced a sweeping investigation Monday of the pharmaceutical industry's pricing practices, jockeying for the upper hand with the Trump administration on an issue that concerns Americans across the political spectrum. Oversight and Reform Committee Chairman Elijah Cummings said he's sent letters to 12 major drugmakers seeking detailed information and documents about pricing practices for brand-name drugs to treat diseases including cancer, diabetes, kidney failure and nerve pain. Cummings, a Maryland Democrat, said he wants to find out why prices have increased so dramatically for some existing medications, as well as how drug companies determine the prices of newly introduced medicines.

  • CNBC6 days ago

    House Democrats launch drug-pricing probe into a dozen major health-care companies

    AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.

  • Benzinga6 days ago

    How To Approach Q4 Earnings: The Global Perspective

    Fears of a gradually slowing global economy started emerging mid-2018, alongside U.S. tariffs on goods from Canada, Mexico, the EU and, of course, China. More recent concerns about anemic oil and commodity prices and rapidly contracting productivity in China have only added to the uncertainty. One useful tool for getting an idea of a company's ability to weather the fallout of events like this is debt to capital ratios against its valuation and cash flow statistics.

  • Modern Value Investing: Adding to the Value Investing Toolbox
    GuruFocus.com6 days ago

    Modern Value Investing: Adding to the Value Investing Toolbox

    In chapter four of Sven Carlin's book, "Modern Value Investing: 25 Tools to Invest With a Margin of Safety in Today's Financial Environment," the author observed that almost a century had passed since Benjamin Graham laid out the foundational principles of value investing. Warning! GuruFocus has detected 7 Warning Signs with PFE. According to Carlin, investors should not be afraid to pay taxes.

  • MarketWatch6 days ago

    Pfizer's new drug applications for tafamidis accepted for filing by FDA

    Pfizer Inc's two new drug applications for tafamidis for the treatment of a fatal heart condition have been accepted for filing by the U.S. Food and Drug Administration, the company announced Monday. Pfizer submitted the NDAs based on two forms of the drug for treatment of transthyretin amyloid cardiomyopathy, a fatal condition where a transport protein in the blood misfolds and results in a build-up of amyloid fibrils in the heart, the company said. One of those forms, tafamidis meglumine, was granted priority review and has a July 2019 Prescription Drug User Fee Act target date for FDA review, the company said. A Phase 3 study of tafamidis meglumine met its primary endpoint, showing a significant reduction in mortality and frequency of cardiovascular-related hospitalizations over 30 months compared to placebo. Shares of Pfizer have fallen 1.8% in the year to date, while the S&P 500 has gained 3.5%.

  • Business Wire6 days ago

    US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy

    —FDA grants a Priority Review based on Phase 3 ATTR-ACT study findings in ATTR-CM—

  • Here Are the 2019 Dogs of the Dow
    Motley Fool7 days ago

    Here Are the 2019 Dogs of the Dow

    Dividend investors flock to this strategy to simplify their investing and earn solid returns. Here's how to join them this year.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool8 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?

  • TheStreet.com9 days ago

    Pfizer and the Urge to Merge

    Investors may have noticed Thursday's 2.4% decline in the market price for Dow Jones Industrial Average component Pfizer . PFE was easily the worst performer among those 30 blue chips on a day that saw the average rise by half of one percent.

  • For Esperion Therapeutics, 2019 Could Be a Big Year
    Motley Fool9 days ago

    For Esperion Therapeutics, 2019 Could Be a Big Year

    The developer of a new cholesterol-lowering treatment is on a path toward commercialization.

  • TheStreet.com9 days ago

    This Market May Just Be in an Uptrend: Market Recon

    Are equity markets in a confirmed uptrend? Like the Patellar Reflex, also known commonly as the "knee-jerk", this response is both immediate and involuntary. The S&P 500 now stands at year-to-date gains of 3.6% (This is the eighth business day of the year.) The Nasdaq Composite is now 5.4% higher for 2019.

  • Will Pfizer Join The Buying Spree With This Small Biotech Stock?
    Investor's Business Daily10 days ago

    Will Pfizer Join The Buying Spree With This Small Biotech Stock?

    Amarin stock bounded to a month-high Thursday on a report that Dow Jones component Pfizer could be interested in acquiring it. Deals in the biopharma space have kicked up over the last month.